Neuphoria Therapeutics Inc. (NEUP): R&D Expense
$9.01M
Year ended 2025-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $9.01M | -4.4% | 2025-09-29, From 2024-07-01 |
| 2024-06-30 | $9.42M | -28.0% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $13.07M | n/a | 2024-09-30, From 2022-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2024-03-31 | $184.2K | -8.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗